Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Michael Friis

Head of Equities

Michael Friis portrait

Coverage

HydractAudientesRealfictionShape RoboticsScape TechnologiesGreenMobilityCurasightOrderYOYOPenneoPhotocatOdicoAgillicBawat Water TechnologiesImperoMapsPeopleNNITNordic SolarScandinavian Medical SolutionsWindowMaster InternationalGomSpace GroupCABA CapitalAscelia PharmaEmbla MedicalBioPortoGubraExpreS2ion Biotech Holding

Latest content

ShowingAll content types

Columbus: FY 2025 in line with preliminary results – returns to growth in 2026

Analyst Comment 12.03.2026 klo 10.40 by Michael Friis
Columbus

Gubra – Presentation of Phase 1 Topline Results on ABBV-295 (Recording)

Analyst Comment 10.03.2026 klo 16.10 by Michael Friis
Gubra

Gubra: ABBV-295 data doesn’t seem that far from Eli Lilly's phase 1 data on Eloralintide

Analyst Comment 09.03.2026 klo 16.57 by Michael Friis
Gubra

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

Gubra (One-pager): Enters 2026 with three differentiated obesity candidates — pivotal data readouts expected in 2026

Research 09.03.2026 klo 09.29 by Philip Coombes, Michael Friis
Gubra

GomSpace – 7.6 MEUR contract with VirtuaLabs for RF monitoring satellite constellation

Analyst Comment 04.03.2026 klo 15.13 by Michael Friis
GomSpace Group

Curasight (One-pager): Pivotal data readouts ahead in 2026

Research 03.03.2026 klo 15.25 by Michael Friis
Curasight

MPC Energy Solutions: Recording of preliminary 2025 result presentation

Analyst Comment 27.02.2026 klo 16.13 by Michael Friis
MPC Energy Solutions

Agillic (One-pager) - Strategic reset bearing fruit as earnings momentum continues into 2026

Research 26.02.2026 klo 16.15 by Michael Friis, Victor Skriver
Agillic

Gubra:  CTA submitted for first-in-human study of lead asset GUB-UCN2

Analyst Comment 26.02.2026 klo 09.06 by Michael Friis
Gubra

ExpreS2ion Biotech (One-pager): Progress continues on both pipeline and partner driven programs

Research 25.02.2026 klo 15.19 by Philip Coombes, Michael Friis
ExpreS2ion Biotech Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.